摘要
目的 :同时检测癌基因蛋白EGFR、C erbB 2、CD44v6和P5 3在大肠癌中的表达 ,分析不同表达水平患者组的 3年生存率差异。方法 :对 6 3例存档大肠癌石蜡组织标本进行重新切片 ,采用EGFR、C erbB 2、CD44v6和P5 34种单克隆抗体分别进行免疫组化染色 (SABC法 )。所有病例均随访 3年以上。结果 :全部 6 3例大肠癌中除 4例(6 .3% )无任何 1种癌基因蛋白表达外 ,11例 (17.5 % )表达 1种癌基因蛋白的患者 3年生存率 88.8% ;19例 (30 .2 % )表达 2种癌基因蛋白的患者 3年生存率 70 .5 % ;15例 (2 3.8% )表达 3种癌基因蛋白的患者 3年生存率 5 7.8% ;14例 (2 2 .2 % )表达全部 4种癌基因蛋白的患者 3年生存率 2 2 .2 % ,与前 3组患者的 3年生存率比较差异均有显著性 (P <0 .0 1)。结论 :4种癌基因蛋白同时表达与大肠癌不良预后密切相关。
Objective:To investigate the 3 year survival rate of colorectal cancers which have the expressions of EGFR?C erbB 2?CD44v6 and P53.Methods:Expressions of EGFR?C erbB 2?CD44v6 and P53 were detected with four monoclonal antibodies respectively by immunohistochemical SABC staining in 63 colorectal cancers.All the patients were followed up for 42 months.Results:There were only 4(6.3%) patients with none of EGFR?C erbB 2?CD44v6 and P53 expressions.The 3 year surival rates of 11(17.5%) patients with one expression,19(30.2%) patients with two expressions,15(23.8%) patients with three expressions and 14(22.2%) patients with all four expressions were 88.8%?70.5%?57.8% and 22.2% respectively.The last rate was significant lower compared with anyone of the former three year survival rates( P<0.01 ).Conclusion:A combination of those staining may be proved useful in assessing which patients are at greater risk of poor prognosis.
出处
《武汉大学学报（医学版）》
CAS
2001年第2期176-177,180,共3页
Medical Journal of Wuhan University
